These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15361777)

  • 21. Modulation of 24-h blood pressure profiles: a new target for treatment?
    Palatini P; Parati G
    J Hypertens; 2005 Oct; 23(10):1799-801. PubMed ID: 16148601
    [No Abstract]   [Full Text] [Related]  

  • 22. [Lowering blood pressure with sartans. Are there differences?].
    MMW Fortschr Med; 2002 Nov; 144(47):63. PubMed ID: 12532530
    [No Abstract]   [Full Text] [Related]  

  • 23. Pretreatment levels of plasma renin activity predict ambulatory blood pressure response to valsartan in essential hypertension.
    Minami J; Ohno E; Furukata S; Ishimitsu T; Matsuoka H
    J Hum Hypertens; 2009 Oct; 23(10):683-6. PubMed ID: 19369955
    [No Abstract]   [Full Text] [Related]  

  • 24. [Despite drug treatment, ever second hypertensive patient with morning blood pressure too high].
    MMW Fortschr Med; 2004 Aug; 146(33-34):52. PubMed ID: 15526635
    [No Abstract]   [Full Text] [Related]  

  • 25. Valsartan treatment of hypertension--does VALUE add value?
    Lindholm LH
    Lancet; 2004 Jun; 363(9426):2010-1. PubMed ID: 15207946
    [No Abstract]   [Full Text] [Related]  

  • 26. Evaluating 24-h antihypertensive efficacy by the smoothness index: a meta-analysis of an ambulatory blood pressure monitoring database.
    Parati G; Schumacher H; Bilo G; Mancia G
    J Hypertens; 2010 Nov; 28(11):2177-83. PubMed ID: 20811294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
    White WB; Weber MA; Sica D; Bakris GL; Perez A; Cao C; Kupfer S
    Hypertension; 2011 Mar; 57(3):413-20. PubMed ID: 21282560
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome.
    Ichikawa Y
    Intern Med; 2007; 46(17):1331-6. PubMed ID: 17827829
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: meta-analysis of a clinical database.
    Neutel J; Smith DH
    J Clin Hypertens (Greenwich); 2003; 5(1):58-63. PubMed ID: 12556655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Telmisartan or valsartan alone or in combination with hydrochlorothiazide: a review.
    Lacourcière Y
    Clin Exp Hypertens; 2013; 35(1):50-60. PubMed ID: 22866964
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial.
    White WB; Murwin D; Chrysant SG; Koval SE; Davidai G; Guthrie R
    Blood Press Monit; 2008 Feb; 13(1):21-7. PubMed ID: 18199920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis.
    Georgescu EF; Ionescu R; Niculescu M; Mogoanta L; Vancica L
    World J Gastroenterol; 2009 Feb; 15(8):942-54. PubMed ID: 19248193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of telmisartan on forearm postischemic hyperemia and serum asymmetric dimethylarginine levels.
    Tomiyama H; Yamada J; Koji Y; Shiina K; Yoshida M; Yamashina A
    Am J Hypertens; 2007 Dec; 20(12):1305-11. PubMed ID: 18047921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiology patient page. Angiotensin receptor blockers.
    Terra SG
    Circulation; 2003 Jun; 107(24):e215-6. PubMed ID: 12821593
    [No Abstract]   [Full Text] [Related]  

  • 35. Telmisartan provides superior BP reduction from morning to morning compared to other leading ARBs.
    Cardiovasc J S Afr; 2006; 17(4):210. PubMed ID: 17001428
    [No Abstract]   [Full Text] [Related]  

  • 36. Trough:peak ratio and smoothness index in the evaluation of 24-h blood pressure control in hypertension: a comparative study between valsartan/hydrochlorothiazide combination and amlodipine.
    Palatini P; Malacco E; Di SS; Carretta R; Dorigatti F; Bertocchi F; Mann J
    Eur J Clin Pharmacol; 2002 Jan; 57(11):765-70. PubMed ID: 11868797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ambulatory blood pressure response to once-daily fimasartan: an 8-week, multicenter, randomized, double-blind, active-comparator, parallel-group study in Korean patients with mild to moderate essential hypertension.
    Lee H; Kim KS; Chae SC; Jeong MH; Kim DS; Oh BH
    Clin Ther; 2013 Sep; 35(9):1337-49. PubMed ID: 23932463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of telmisartan treatment on the abdominal fat depot in patients with metabolic syndrome and essential hypertension: Abdominal fat Depot Intervention Program of Okayama (ADIPO).
    Murakami K; Wada J; Ogawa D; Horiguchi CS; Miyoshi T; Sasaki M; Uchida HA; Nakamura Y; Makino H
    Diab Vasc Dis Res; 2013 Jan; 10(1):93-6. PubMed ID: 22561230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging benefits of AT1 receptor antagonists with pleiotropic anti-inflammatory activity.
    Sernia C; Brown L
    Am J Hypertens; 2011 Jul; 24(7):739. PubMed ID: 21681185
    [No Abstract]   [Full Text] [Related]  

  • 40. Plasma renin activity for predicting antihypertensive drug efficacy.
    Blumenfeld JD
    Am J Hypertens; 2008 Jan; 21(1):5-6. PubMed ID: 18091734
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.